In 2016, personalized medicine for IBD has been evolving. Increasing comfort with biosimilar infliximab was achieved with 'real-life' data. Drugs with alternative modes of action confirmed substantial benefit, even in patients failing anti-TNF agents. Adipose-derived mesenchymal stem cells yielded a new treatment option for perianal fistulas.
- Krisztina B. Gecse
- Péter L. Lakatos